Cardiovascular biotech Tenaya Therapeutics has signed a research collaboration agreement with RNAi specialist Alnylam Pharmaceuticals in a deal that includes a $10 million upfront payment and much more in potential milestone payments for Tenaya if the partnership bears fruit.


